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Abstract
Background: Primary ciliary dyskinesia (PCD) and cystic fibrosis (CF) are increasingly compared. There are no chest
magnetic resonance imaging (MRI) comparative studies of PCD and CF. We assessed clinical, functional, microbiological
and MRI findings in PCD and mild CF patients in order to evaluate different expression of lung disease.
Methods: Twenty PCD (15.1 years) and 20 CF subjects with mild respiratory impairment (16 years, 70% with pancreatic
insufficiency) underwent MRI, spirometry, and sputum cultures when clinically stable. MRI was scored using the modified
Helbich system.
Results: PCD was diagnosed later than CF (9.9 versus 0.6 years, p= 0.03), despite earlier symptoms (0.1 versus 0.6 years,
p= 0.02). In the year preceding the study, patients from both groups underwent two systemic antibiotic courses (p= 0.48).
MRI total scores were 11.6 ± 0.7 and 9.1 ± 1 in PCD and CF, respectively. FEV1 and FVC Z-scores were −1.75 (range,
−4.6–0.7) and −0.6 (−3.9–1.8) in PCD, and −0.9 (range, −5.4–2.3) and −0.3 (−3.4–2.5) in CF, respectively. No difference
was found between lung function or structure, despite a higher MRI subscore of collapse/consolidation in PCD
versus CF (1.6 ± 0.1 and 0.6 ± 0.2, p < 0.001). These findings were confirmed after data-control for diagnostic delay.
Pseudomonas aeruginosa and Staphylococcus aureus were more frequent in CF than in PCD (p = 0.05 and p = 0.003,
respectively).
Conclusions: MRI is a valuable radiation-free tool for comparative PCD and CF lung disease assessment. Patients with
PCD may exhibit similar MRI and lung function changes as CF subjects with mild pulmonary disease. Delay in PCD
diagnosis is unlikely the only determinant of similarities.
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Background
Primary ciliary dyskinesia (PCD) is characterized by altered
ciliary beat frequency and/or pattern resulting in impaired
airways clearance [1]. Clinical manifestations include neo-
natal respiratory distress, recurrent upper airway infections
and chronic suppurative lung disease. Due to phenotypical
similarities with cystic fibrosis (CF) but the relative
infrequency of PCD, management of the latter is borrowed
from CF protocols for many therapeutic strategies, such
as clearance techniques [2]. Unlike for CF, however, the
efficacy of such treatments for PCD is less obvious [3, 4].
The explanation likely resides in the different structure
and pathophysiology of these entities [5]. Hence, studies
to better define the inherent differences between the two
conditions might lead to clarify the underlying mecha-
nisms of PCD progression [6].
Assessment of CF and PCD lung disease traditionally
includes spirometry and chest computed tomography
(CT). Despite the availability of several functional
parameters, FEV1 still remains a convenient and widely
used outcome for both clinical and research purposes.
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Nevertheless, FEV1 deteriorates long after structural
damage occurs [7–10], making CT essential in monitoring
early and late lung changes in both conditions [1, 11]. How-
ever, the perceived risk of ionizing radiation, particularly in
the young, limits frequent CT scans. Thus, chest magnetic
resonance imaging (MRI) might be a valuable radiation-free
alternative [12–14]. Even though its application in pulmon-
ary imaging has long been limited by technical problems
such as the low proton density of the lung, increasing
evidence supports the reliability of MRI in assessing lung
structural damage [12, 13]. Nevertheless, limited access to
technology, poor experience in image interpretation, long
acquisition times and high costs have prevented chest MRI
from being routinely adopted in CF and PCD management.
A recent comparative CT study assessed lung structure in
PCD and CF [15] but to our knowledge, no such compara-
tive study using chest MRI has been undertaken to date. The
primary aim of the present study was to comparatively assess
lung structure in patients with PCD or mild CF by means of
chest MRI. The secondary aim was to compare clinical,
functional, and microbiological findings in the two cohorts,
in order to evaluate different expressions of lung disease.
Methods
Study design and patients
This was a prospective, single-center comparative study
of PCD and CF lung disease. Between January 2014 and
May 2015 we enrolled all mild CF patients, selected on
the basis of previously published functional criteria [16],
and PCD patients consecutively seen at the Department
of Translational Medical Sciences, Federico II University,
Naples, who fulfilled the following inclusion criteria:
stable lung disease, without acute dyspnea or cough, no
pulmonary function changes and no requirements for
intravenous antibiotics in the previous 4 weeks [10, 17].
Subjects with acute respiratory infection, developmental
delay, or other conditions that could compromise com-
pliance to MRI or spirometry, e.g., age < 6 years and/or
claustrophobia, were excluded. No CF patient had
undergone neonatal screening, and CF had been diag-
nosed according to published criteria [18]. Pancreatic
insufficiency was defined as stool elastase < 100 μg/g.
Abnormal motility and ultrastructural analysis of nasal
cilia on transmission electron microscopy confirmed
PCD diagnosis [19]. Diagnostic criteria of the enrolled
PCD patients were also reviewed according to the recently
published international guidelines which require typical
ciliary ultrastructure or mutations in PCD causing genes
for positive diagnosis, and very low nasal nitric oxide
combined with consistent findings at high-speed video
microscopy analysis for highly likely diagnosis [20].
At our center, CF patients routinely undergo chest
high-resolution CT (HRCT) about every two years [21],
whereas the time-interval between consecutive CT scans
changes on a case by case basis for PCD. Therefore,
when a HRCT was scheduled for routine assessment
during follow-up, we presented the study to patients
and/or legal guardians, and asked them to undergo chest
MRI, spirometry and sputum culture on the same day.
We used this approach to verify the reliability of chest
MRI scans by real time comparison to CT, the gold
standard for lung abnormalities. Clinical data and spu-
tum culture results from the preceding 12 months were
collected.
All patients routinely undergo 3-monthly visits. PCD
treatment strategy derives from CF care, and includes
twice daily chest physiotherapy preceded by nebulized
hypertonic saline, and oral and/or intravenous antibi-
otics based on sputum culture in case of exacerbations.
Inhaled antibiotics and/or dornase alpha in PCD are
not used in Italy, since they are approved for CF only.
Written informed consent was obtained from patients
and/or legal guardians. The study was approved by the
local Ethical Committee (Comitato Etico per le Attività
Biomediche, Federico II University; approval number
184/2014).
Spirometry
Spirometry was performed according to published criteria
[22]. We expressed FVC, FEV1, and FEF25–75 as Z-scores
[23]. We considered FEV1 as the primary outcome
parameter to assess differences between groups, and a
Z-score < −1.64 as abnormal [23].
Microbiology data
Sputum cultures obtained during the 12 months preced-
ing enrolment were collected. Chronic airway infection
was defined when the same pathogen was detected in at
least three consecutive cultures within 6 months and
after adequate antibiotic therapy.
MR scanning
MRI was performed with a 3.0-T MR scanner (Magnetom
Trio, Siemens Erlangen, Germany), a maximum gradient
strength of 40 mT/m, a slew rate of 200 mT/m/ms, and 32
radiofrequency channels. We used a dedicated 12-element
integrated matrix coil system that covered the whole thorax
for signal reception. It consisted of 1 anterior and 1
posterior flexible phased-array coil, each containing a set of
6 receiver elements. The applied sequence was a T2-
weighted half-Fourier single-shot turbo spin-echo (HASTE)
sequence, performed using an electrocardiograph-gating to
reduce cardiac motion artifacts, and respiratory-gating by a
navigator signal that monitored the diaphragm position.
The field of view was patient-adapted. Sequence pa-
rameters were: repetition time/echo time/flip angle,
infinite/92 milliseconds/150 degrees; 25 to 30 slices;
slice thickness, 5 mm; distance factor, 20%; transversal
Maglione et al. Italian Journal of Pediatrics  (2017) 43:34 Page 2 of 9
orientation (matrix, 380 256); acquisition time, approxi-
mately 90 s. Parallel imaging was used for all measure-
ments using the GRAPPA (Generalized Autocalibrating
Partially Parallel Acquisition) algorithm with an acceler-
ation factor of 2 and 24 reference lines. No patient
required sedation. Door-to-door time was 5.5 min (range,
5–8). All MR studies were of diagnostic quality and were
well tolerated.
HRCT scanning
For all patients CT was part of the routine assess-
ment and did not represent a study procedure. The
HRCT scan was performed with a 4-slice CT scanner
(Aquilion, Toshiba, Japan) and a bodyweight adapted
protocol (adolescents: 120 kV, 140 mAs; children over
45 kg: 120 kV, 65 mAs; children over 35 kg: 120 kV,
45 mAs; children below 35 kg: 120 kV, 30 mAs), with
1x4 mm collimation, 10 mm gap, 0.5 s rotation time,
automatic exposure control, multiple inspiratory
breath holds of 3 s each, with the patient in a supine
position. Scanning extended from the lung apices to
below the costophrenic angles. The field of view of
each sequence was patient adapted. Images were
reconstructed using a high-resolution algorithm. The
total time for acquisition of the images was approxi-
mately 5 min, including positioning of the patient.
Contrast medium was not administered. For docu-
mentation of radiation exposure, the dose length
product was recorded, and the effective dose (E) and
the weighted CT dose index were calculated. A lung
window setting (+1500/-500 Hounsfield unit) was
used for image analysis. Images were reviewed on a
workstation (iMac MacOS 10.4/OsiriX v.2.7.5 32 bit).
Image evaluation
After removal of identifying information, MRI and CT im-
ages, in a randomized patient order, were evaluated to
reach consensus between a radiologist and a pediatric pul-
monologist with more than 10 years of experience in chest
imaging interpretation. In case of disagreement between
the two observers, the debated abnormality was scored by
the most trained rater. The observers were not directly
involved in the patients’ care, and, with the exception of
subjects with situs viscerum inversus who were easily
identifiable as PCD, they were blinded to any clinical and
previous radiological data that could bias interpretation.
To avoid recall bias, and to prevent raters from being
influenced by a previously scored CT while evaluating MR
images, CT scans were scored at least 6 weeks after MR
images. Further details on image evaluation criteria are
reported in the Additional file 1. The scoring system used
is detailed in the Additional file 2.
Statistical analysis
Data are presented as median and ranges, unless other-
wise stated. The Mann–Whitney U test assessed differ-
ences in clinical, functional and structural parameters
between groups. Comparisons of functional and struc-
tural parameters were reassessed by one-way analysis of
covariance to control for diagnostic delay, which was
used as covariate. This adjustment allowed to compare
lung imaging and lung function data from the two
groups undoing the influence of diagnostic delay, which
was significantly higher in PCD than in CF. Statistical
significance of intragroup comparisons was not deter-
mined due to low statistical power deriving from small
sample size. Fisher’s exact test was used for categorical
variables. Spearman correlation coefficient assessed the
relationships among variables. Statistical significance was
set at a p-value of ≤0.05. Data were analyzed with a
statistical software package (SPSS-PC, version 13.0;
SPSS; Chicago, IL).
Results
Thirty-two CF and 28 PCD subjects were eligible. Due
to acute respiratory infection 13 subjects (7 CF; 6 PCD)
were excluded. Of the remaining, 4 CF and 2 PCD
subjects refused MRI due to claustrophobia. One CF
patient underwent MRI, but was excluded due to poor
compliance resulting in low-quality images. Table 1
summarizes clinical, anthropometric, lung function and
microbiological findings from the forty patients ultim-
ately enrolled (20 with PCD, 20 with CF). Cilia ultra-
structure of patients with PCD is reported in the
Additional file 3. According to the recently published
guidelines on PCD diagnosis [20], 16 out of 20 patients
met the criteria for a positive PCD diagnosis, due to hall-
mark ciliary ultrastructure defects. The four remaining
patients had a combination of non-typical ciliary defects,
very low nasal nitric oxide, and static or circling cilia at
the motility study, thus meeting the definition of highly
likely PCD diagnosis [20].
No differences in age, gender and anthropometric
parameters were found between the groups. Pancreatic
insufficiency was detected in 70% of CF patients. Des-
pite earlier onset of respiratory symptoms (p = 0.02),
PCD was diagnosed later than CF, with a delay of
approximately 9 years (p = 0.03). Duration of follow-up
at a tertiary center was significantly longer in CF than
PCD (p = 0.009). The number of systemic antibiotic
courses and hospital admissions during the previous
12 months was comparable in the groups. Similarly, no
difference emerged from the comparison between func-
tional parameters. No difference was found between
PCD and CF in the proportion of subjects with a FEV1
Z-score < −1.64 (50 and 35%, respectively, p = 0.5).
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Nine PCD (45%) and 15 CF patients (75%) had
complete microbiological data, whereas 11 PCD and 5
CF subjects had sputum cultures performed every 4–6
months during the preceding year. Compared to PCD,
CF subjects showed a significantly higher prevalence of
Pseudomonas aeruginosa isolation in at least one sputum
sample during the previous year (p = 0.05), despite no
difference in the prevalence of chronic infection.
Staphylococcus aureus was more frequently isolated in
CF than PCD (p = 0.003), whereas no difference was
found in the prevalence of both Haemophilus influenzae
isolation and chronic infection between the groups.
Table 2 summarizes median MRI and CT scores from
PCD and CF. For both techniques, total and specific
scores were not different, although, both at MRI and
CT, severity of collapse/consolidation subscore was
higher in PCD than CF (p < 0.001). Total scores were
slightly lower in pancreatic sufficient versus pancreatic
insufficient CF at both MRI and CT [8.5 (0–13) versus
11.5 (1–15) and 9 (0–13) versus 12 (1–15), respectively].
Total MRI and CT scores were not different in PCD
versus CF (p = 0.23 and p = 0.21, respectively).
In PCD and CF, total MRI score was in the mild range
(0–9) in 15 and 45%, and in the moderate range (10–18)
in 85 and 55% of cases, respectively (p > 0.05 for both
comparisons).
Image evaluation in PCD and CF showed excellent
agreement between the techniques for all scores (r > 0.9).
We could not compute agreement between CT and MRI
scores for extent of CF sacculations/abscesses, severity
Table 1 Characteristics of patients with PCD and CF
PCD CF p
N 20 20
Male : Female 12:8 13:7 1
Age (yrs) 15.1 (8.7–29.4) 16 (8–26) 0.60
Age at diagnosis (yrs) 9.9 (0.1–20.5) 0.6 (0–16) 0.03
Age at onset of respiratory symptoms (yrs) 0.1 (0.1–4) 0.6 (0–13) 0.02
Duration of follow-up at tertiary center (yrs) 6.9 (0.1–27.2) 14.5 (0.1–25.9) 0.009
Height (Z-score) −0.71 (−2.55–1.81) −0.47 (−2.41–1.5) 0.88
Weight (Z-score) 0.34 (−3.71–2.72) −0.12 (−3.74–1.43) 0.22
BMI (Z-score) 0.77 (−2.84–2.7) 0.39 (−2.53–1.88) 0.13
Pancreatic insufficiency, n (%) NA 14 (70) –
Nasal nitric oxide (ppb) 14 (5–54) NA –
Situs viscerum inversus, n (%) 12 (60) NA –
Systemic antibiotic courses (previous 12 months) 2 (0–7) 2 (0–6) 0.48
Hospital admissions (previous 12 months) 0 (0–1) 0 (0–5) 0.38
FEV1 (Z-score) −1.75 (−4.6–0.7) −0.9 (−5.4–2.3) 0.24
FVC (Z-score) −0.6 (−3.9–1.8) −0.3 (−3.4–2.5) 0.37
FEV1/FVC (Z-score) −1.6 (−3.5–0.1) −1.1 (−4.2–1.1) 0.24
FEF25–75 (Z-score) −2 (−4.4–0.1) −1.2 (−5.5–1.1) 0.24
Sputum Microbiology
Chronic infection by P. aeruginosa 1/20 3/20 0.60
Chronic infection by H. influenzae 6/20 2/20 0.23
P. aeruginosa (≥1 sample) 4/20 11/20 0.05
H. influenzae (≥1 sample) 15/20 11/20 0.32





Data are presented as median and ranges (in parenthesis)
NA not applicable
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of bullae and severity of emphysema, because of the
constant value of these categories at CT and MRI in all
subjects. Similarly, no agreement was calculated for MRI
severity of PCD bullae due to the constant value of this
category. Only severity of emphysema showed poor
agreement (r = 0.44) between PCD CT and MRI score.
Figs. 1a and b are examples of chest MRI from a PCD
and a CF patient, respectively.
Total MRI score was significantly related to FEV1
Z-score in PCD (r = −0.45, p = 0.04) and CF (r = −0.43,
p = 0.05).
Due to relevant difference in age at diagnosis between
PCD and CF, we comparatively re-assessed lung function
and structure after control for diagnostic delay. We con-
firmed our original findings, as no differences emerged
between PCD and CF for spirometry and MRI or CT
scores (Table 3). The higher score for severity of
collapse/consolidation in PCD was confirmed after cor-
rection for diagnostic delay.
Discussion
Recently CF and PCD have been increasingly compared
[15, 24–29]. To our knowledge, this is the first study
that comparatively assessed PCD and CF lung disease
using MRI. Our main finding is the absence of striking
differences in lung function and structure between the
two cohorts. Actually, we found a significant difference
between patients’ age at PCD or CF diagnosis, hence
follow-up was longer in CF. We initially guessed that
PCD deteriorated as CF because diagnosis occurred late
and patients were referred to a tertiary care center after
longer periods of inadequate management. Surprisingly,
once controlled for diagnostic delay, the absence of any
difference between the groups was confirmed, with the
only exception of the collapse/consolidation subscore
Table 2 Chest MRI and CT scores of patients with PCD and CF
MRI CT
PCD CF p PCD CF p
Severity of bronchiectasis 1.6 ± 0.1 1.5 ± 0.2 0.70 1.7 ± 0.2 1.5 ± 0.2 0.48
Severity of peribronchial wall thickening 1.7 ± 0.1 1.4 ± 0.2 0.09 1.8 ± 0.09 1.5 ± 0.1 0.14
Extent of bronchiectasis 1.9 ± 0.2 2 ± 0.2 0.49 1.9 ± 0.2 2 ± 0.2 0.58
Extent of mucous plugging 1.6 ± 0.2 1.2 ± 0.2 0.28 1.7 ± 0.2 1.3 ± 0.2 0.36
Extent of sacculations or abscesses 0.05 ± 0.05 0 0.33 0.05 ± 0.05 0 0.33
Generation of bronchial divisions involved
(bronchiectasis or plugging)
2.9 ± 0.1 2.3 ± 0.2 0.07 2.9 ± 0.1 2.3 ± 0.2 0.07
Severity of bullae 0 0 – 0.2 ± 0.2 0 0.16
Severity of emphysema 0.1 ± 0.07 0 0.16 0.1 ± 0.07 0 0.16
Severity of collapse or consolidations 1.6 ± 0.1 0.6 ± 0.2 <0.001 1.6 ± 0.1 0.6 ± 0.2 <0.001
Total score 11.6 ± 0.7 9.1 ± 1 0.23 12 ± 0.8 9.3 ± 1 0.21
Data are presented as mean and standard error of the mean
Fig. 1 Transversal MR images of a 14–year-old girl with PCD and
situs viscerum inversus showing an area of consolidation in the
middle lobe (a), and of a 15–year-old boy with CF showing an area
of consolidation in the lingula and sparse bronchiectasis in the left
lower lobe (b)
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that was persistently more severe in PCD. Overall, these
data add further evidence to the widespread concept that
PCD is not the mild disease believed.
The relevant delay in the ultimate diagnosis is univer-
sally recognized in PCD [1, 30], and we confirm it. What
additionally emerges from current data is that a delayed
diagnosis is not the sole responsible for the similarities
found, hence further explanation should be provided.
Despite counterintuitive, the lack of association between
early PCD diagnosis and better pulmonary outcomes,
strongly suggested by our results, has been highlighted
previously [31, 32]. Furthermore, a recent longitudinal
study of adult PCD subjects has confirmed that, even
though negatively associated with baseline FEV1, age at
diagnosis does not correlate with longitudinal functional
measurements, thus raising doubts on the real impact of
optimal management at an early stage on the subsequent
disease progression [33]. These studies did not correlate
chest CT scores with age at diagnosis, but it is reason-
able to hypothesize that, likewise functional impairment,
also structural abnormalities are poorly affected by it.
Nevertheless, the controversy surrounding the associ-
ation between age at PCD diagnosis and lung function
impairment clearly brings into focus the need for future
larger studies.
It is well known that in CF chronic depletion of pericili-
ary layer volume results in hyperviscous mucus layer ad-
hesion to cells, thus inhibiting cough clearance [34].
Conversely, the PCD periciliary layer volume is apparently
normal and airway surface well hydrated, hence cough-
dependent mucus clearance is preserved [35]. However,
despite distinct basic defects [19, 36], CF and PCD share a
common hallmark, i.e., retention of airways mucus and
growth of biofilms [5, 37]. Although we do not provide
data on therapeutic adherence, the poorer PCD patients’
compliance to treatment in our practice might explain the
similarities we found, despite comparable time interval be-
tween visits. In PCD poor compliance to treatment likely
derives from unawareness of potential threats of the dis-
ease, especially if inadequately treated [38]. Conversely,
CF patients, particularly those with good nutritional status
like ours, generally show adequate prescriptions adher-
ence [39]. Inhaled antibiotics and dornase alpha, which in
Italy are authorized only for CF, are not routinely used
[40], and this might help interpreting our findings. Future
comparative studies might realize novel PCD management
strategies, and the efficacy of drugs not routinely used in
PCD should be further investigated. A final, critical point
is that the genetic background may influence PCD lung
disease expression [41]. As we cannot provide PCD geno-
type, a selection bias is not excluded.
Few original studies have compared PCD and CF lung
disease [15, 25]. A comparative analysis of chest CT, also
including PCD patients from our center, reported less
lung changes in PCD than CF [25]. In that study, PCD
patients were compared to a previously published CF
cohort undergoing chest imaging for clinical reasons,
unlike current CF subjects [42]. The difference between
imaging scoring systems makes any comparison between
the two studies unreliable. A recent study found that
Table 3 Lung imaging and lung function of PCD and CF patients controlled for diagnostic delay
MRI CT
PCD CF p PCD CF p
Severity of bronchiectasis 1.6 ± 0.2 1.6 ± 0.2 0.9 1.7 ± 0.2 1.6 ± 0.2 0.9
Severity of peribronchial wall thickening 1.7 ± 0.2 1.5 ± 0.2 0.4 1.8 ± 0.1 1.7 ± 0.1 0.4
Extent of bronchiectasis 1.8 ± 0.2 2.2 ± 0.2 0.3 1.8 ± 0.2 2.3 ± 0.2 0.3
Extent of mucous plugging 1.6 ± 0.2 1.3 ± 0.3 0.4 1.6 ± 0.3 1.5 ± 0.3 0.5
Extent of sacculations or abscesses 0.02 ± 0.04 0.03 ± 0.04 0.2 0.02 ± 0.04 0.03 ± 0.04 0.2
Generation of bronchial divisions involved
(bronchiectasis or plugging)
2.8 ± 0.2 2.7 ± 0.2 0.1 2.8 ± 0.2 2.6 ± 0.2 0.1
Severity of bullae 0 0 – 0.1 ± 0.1 0.1 ± 0.1 0.1
Severity of emphysema 0.08 ± 0.05 0.03 ± 0.06 0.2 0.06 ± 0.05 0.04 ± 0.06 0.1
Severity of collapse or consolidations 1.5 ± 0.2 0.8 ± 0.2 <0.001 1.5 ± 0.2 0.8 ± 0.2 <0.001
Total score 11.0 ± 0.9 10.1 ± 0.9 0.1 11.4 ± 0.9 10.4 ± 0.9 0.1
Lung function PCD CF p
FVC (Z-score) −0.3 ± 0.3 −0.5 ± 0.3 0.08
FEV1 (Z-score) −1.4 ± 0.4 −1.4 ± 0.4 0.1
FEF25–75 (Z-score) −2.0 ± 0.4 −1.8 ± 0.4 0.4
FEV1/FVC (Z-score) −1.7 ± 0.3 −1.4 ± 0.3 0.5
Data are presented as mean and standard error of the mean
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lung disease severity at CT was similar between PCD
and pancreatic sufficient CF, but significantly higher in
pancreatic insufficient CF [15]. Conversely, in the current
study we did not find differences between the two diseases
in terms of lung function and structure, except collapse/
consolidation. Comparing that study population with ours,
it is worth noting that age at enrolment was similar in
PCD and CF. Nevertheless, our CF patients had milder
pulmonary involvement, with fewer exacerbations and less
chronic Pseudomonas aeruginosa infection rate (15% ver-
sus 51%, respectively) than the comparison cohort. More
importantly, in the current study lung damage at MRI was
in the moderate range in approximately half of CF versus
two thirds of PCD, with the remaining subjects from both
groups showing mild impairment. Actually, FEV1 Z-score
was normal in our CF and abnormal in our PCD subjects
(−0.9 versus −1.75, respectively), although the difference
was not significant. Overall, these data suggest that the CF
patients from the two studies differ in disease severity,
despite comparable lung function, with milder pulmonary
disease in our cohort [15]. Unfortunately, the small num-
ber of our CF patients with or without pancreatic insuffi-
ciency precluded the comparison between these CF
subgroups. Furthermore, the limited sample size may have
biased our findings.
Our study has both strengths and limitations. Undoubt-
edly the use of a non-invasive tool, namely MRI, is an
element of novelty in the comparison of CF and PCD.
Chest MRI has been used in both diseases separately, and
its reliability has been widely demonstrated through com-
parisons with traditional techniques [12, 13]. We found an
excellent agreement between MRI and CT for most abnor-
mality parameters in both PCD and CF. However, al-
though CT is a useful staging test, it is impractical for
monitoring lung disease because of radiation burden [43].
Conversely, spirometry is an insensitive marker of lung
disease progression [10, 42]. In this setting, MRI is attract-
ive and reliable as radiation-free option [13, 44, 45]. In
addition, the re-analysis of data after control for diagnostic
delay highlighted that the lack of differences between PCD
and CF is unlikely due to prolonged untreated PCD.
Our study has also limitations. First, as shown by chest
imaging scores and spirometry, our analysis compared
mild CF subjects and PCD patients mostly presenting
mild-to-moderate functional and structural impairment,
with virtually no patients showing more severe disease.
Moreover, the modified Helbich score does not take into
account the non-comparable involvement of different
lobes. However, we opted for this scoring system as it
was previously used in CF and PCD, and because the
observers were already trained in it. In addition, as pre-
viously stated, enrolled CF patients presented mild lung
disease, unlike PCD subjects whose pulmonary impair-
ment was likely more severe. Indeed, despite CF and
PCD recruitment was timed to coincide with a routine
CT, the lack of a shared protocol defining the time inter-
val between scans in PCD might have determined the
enrolment of more severe PCD. Similarly, it could also
be speculated that the enrolled PCD patients have more
severe disease entailing referral compared to those with
a late or totally missed diagnosis, and this could further
bias results. Indeed, the majority of our PCD patients
fully met the stringent definition for positive PCD diag-
nosis recently formalized by international guidelines and
only in four of them findings from several diagnostic
tests made PCD diagnosis “highly likely”. For these sub-
jects genetic testing is certainly warranted, but given the
highly suggestive clinical picture, the very low nasal
nitric oxide levels, the abnormal cilia motility and the ul-
trastructural defects found – even though not hallmark
of PCD – we felt they could be included in our PCD co-
hort. Of course, we deeply commend the ERS Task Force
for the effort in standardizing the diagnostic pathway in
PCD. Their guidelines, requiring an interaction between
more diagnostic tools to achieve a definite diagnosis, will
certainly help in the characterization of patients and in
correlating disease severity with cilia ultrastructure and
motility, and with the genetic background. This will also
strengthen data from multicenter PCD studies enrolling
patients whose diagnosis will no longer be questioned.
The mentioned drawbacks, together with the limited
sample size, make it difficult to generalize the data.
Further research on larger populations from multicenter
sites, possibly including all ranges of severity is needed to
verify whether our results are replicable. Finally, longi-
tudinal studies comparing PCD and CF from early life
to adolescence/adulthood would likely improve our
knowledge on differences in the speed of lung disease
progression between the two entities.
Conclusions
This comparative study of PCD and CF suggests that the
two conditions may share similar lung function and MRI
changes and confirms that chest MRI is a valuable
radiation-free tool. Comparative studies of PCD and CF
lung disease may hopefully also help to develop PCD-
specific protocols not derived from CF.
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